Risk charts to identify low and excessive responders among first-cycle IVF/ICSI standard patients

Reproductive BioMedicine Online

Volumn 22, Issue 1, 2011, Pages 50-58

  La Cour Freiesleben, N ^a   Gerds, T A ^b   Forman, J L ^b   Silver, J D ^b   Nyboe Andersen, A ^a   Popovic Todorovic, B ^c  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

Excessive response; Low response; Ovarian stimulation; Predictive factors; Prognostic models; Risk charts

Indexed keywords

FOLLITROPIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ANTRAL FOLLICLE COUNT; ARTICLE; BODY MASS; BODY WEIGHT; BOOTSTRAPPING; CONTROLLED STUDY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; RISK ASSESSMENT; RISK FACTOR;

ADULT; EVIDENCE-BASED MEDICINE; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; INFERTILITY, FEMALE; MODELS, BIOLOGICAL; OVARIAN FOLLICLE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; PREVALENCE; RECOMBINANT PROTEINS; RISK ASSESSMENT; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 78650516784     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2010.08.010     Document Type: Article

References (48)

1. A.N. Andersen, P. Devroey, J.C. Arce for the MERIT Group Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial Hum. Reprod. 21 2006 3217 3227
2. Asian Puregon Study Group E.H.M. Hoomans, and B.B. Mulder A group-comparative, randomized, double-blind comparison and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon®) in Asian women undergoing ovarian stimulation for IVF/ICSI J. Assist. Reprod. Genet. 19 2002 470 476
3. L.F. Bancsi, F.J. Broekmans, and M.J. Eijkemans Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve Fertil. Steril. 77 2002 328 336
4. T. Brodin, T. Bergh, and L. Berglund Menstrual cycle length is an age-independent marker of female fertility: results from 6271 treatment cycles of in vitro fertilization Fertil. Steril. 90 2008 1656 1661
5. S.L. Broer, B.W.J. Mol, and D. Hendriks The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Fertil. Steril. 91 2009 705 714
6. B. Efron, and R. Tibshirani Improvements on cross-validation: the.632+ bootstrap method J. Am. Stat. Assoc. 92 1997 548 560
7. T. Eldar-Geva, A. Ben-Chetrit, and I.M. Spitz Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome Hum. Reprod. 20 2005 3178 3182
8. E.A. Elgindy, D.O. El-Haieg, and A. El-Sebaey Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients Fertil. Steril. 89 2008 1670 1676
9. B.C.J.M. Fauser, K. Diedrich, P. Devroey Evian Annual Reproduction Workshop Group 2007 Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation Hum. Reprod. Update 14 2008 1 14
10. N.C. Freiesleben, K. Lossl, and J. Bogstad Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study Hum. Reprod. 24 2009 2523 2530
11. T.A. Gerds, T. Cai, and M. Schumacher The performance of risk prediction models Biom. J. 50 2008 457 479
12. D.J. Hand Construction and Assessment of Classification Rules 1997 Wiley Chichester
13. J. Hilden Prevalence-free utility-respecting summary indices of diagnostic power do not exist Stat. Med. 19 2000 431 440
14. R. Homburg The management of infertility associated with polycystic ovary syndrome Reprod. Biol. Endocrinol. 1 2003 109
15. C.M. Howles, H. Saunders, and V. Alam The FSH Treatment Guidelines Clinical Panel. Predictive factors, a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients Curr. Med. Res. Opin. 22 2006 907 918
16. M. Ikeda, T. Ishigaki, and K. Yamauchi Relationship between Brier score and area under the binormal ROC curve Comput. Methods Programs Biomed. 67 2002 187 194
17. K. Jayaprakasan, B. Campbell, and J. Hopkisson A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation Fertil. Steril. 93 2010 855 864
18. M. Khairy, A. Clough, and T. El-Toukhy Antral follicle count at down-regulation and prediction of poor ovarian response Reprod. Biomed. Online 17 2008 508 514
19. N.A. Klein, and M.R. Soules Endocrine changes of the perimenopause Clin. Obstet. Gynecol. 41 1998 912 920
20. N.A. Klein, A.J. Harper, and B.S. Houmard Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development? J. Clin. Endocrinol. Metab. 87 2002 5746 5750
21. E.R. Klinkert, F.J.M. Broekmans, and C.W.N. Looman Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial Hum. Reprod. 20 2005 611 615
22. J. Kwee, M.E. Elting, and R. Schats Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization Reprod. Biol. Endocrinol. 5 2007 9
23. A. La Marca, S. Giulini, and A. Tirelli Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology Hum. Reprod. 22 2007 766 771
24. S.M. Nelson, R.W. Yates, and R. Fleming Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles - implications for individualization of therapy Hum. Reprod. 22 2007 2414 2421
25. S.M. Nelson, R.W. Yates, and H. Lyall Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception Hum. Reprod. 24 2009 867 875
26. F. Oliviennes, C.M. Howles, and A. Borini Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study Reprod. Biomed. Online 18 2008 195 204
27. H.J. Out, D.D.M. Braat, and B.M.E. Lintsen Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation Hum. Reprod. 15 2000 29 35
28. H.J. Out, I. David, and R. Ron-El A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles Hum. Reprod. 16 2001 1104 1109
29. S. Palomba, R. Oppedisano, and A. Tolino Metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview Reprod. Biomed. Online 16 2008 327 335 (Pubitemid 351419450)
30. M.S. Pepe, H. Janes, and G. Longton Limitations of the odds ration in gauging the performance of a diagnostic, prognostic, or screening marker Am. J. Epidemiol. 159 2004 882 890
31. B. Popovic-Todorovic, A. Loft, and H.E. Bredkjæer A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a "standard" dose of 150 IU/day in "standard" patients undergoing IVF/ICSI treatment Hum. Reprod. 18 2003 2275 2282
32. B. Popovic-Todorovic, A. Loft, and A. Lindhard A prospective study of predictive factors of ovarian response in "standard" IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage nomogram Hum. Reprod. 18 2003 781 787
33. B. Popovic-Todorovic, A. Loft, and S. Ziebe Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle Acta Obstet. Gynecol. Scand. 83 2004 842 849
34. R Development Core Team, 2008. R: A Language and Environment for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0, URL: http://www.R-project.org.
35. D.A. Redelmeier, D.A. Bloch, and D.H. Hickam Assessing predictive accuracy: how to compare Brier scores J. Clin. Epidemiol. 44 1991 1141 1146
36. R.M. Riggs, E.H. Duran, and M.W. Baker Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B and age Am. J. Obstet. Gynecol. 199 2008 202.e1 202.e8
37. G.J. Scheffer, F.J.M. Broekmans, and L.F. Bancsi Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts Ultrasound Obstet. Gynecol. 20 2002 270 275
38. B.M. Sherman, and S.G. Korenman Hormonal characteristics of the human menstrual cycle throughout reproductive life J. Clin. Invest. 55 1975 699 706
39. E.W. Steyerberg Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating 2008 Springer
40. E.W. Steyerberg, F.E. Harrell, and G.J.J.M. Borsboom Internal validation of predictive models: efficiency of some procedures for logistic regression analysis J. Clin. Epidemiol. 54 2001 774 781
41. The Latin-American Puregon IVF Study Group A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization Fertil. Steril. 76 2001 950 956
42. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group March 2-3, 2007, Thessaloniki, Greece Consensus on infertility treatment related to polycystic ovary syndrome Fertil. Steril. 89 2008 505 522
43. A.E. Treloar, R.E. Boynton, and B.G. Behn Variation of the human menstrual cycle through reproductive life Int. J. Fertil. 12 1967 77 126
44. M.H.A. van Hooff The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? J. Assist. Reprod. Genet. 12 1995 233 235
45. I.A.J. van Rooij, F.J.M. Broekmans, and E.R. te Velde Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve Hum. Reprod. 17 2002 3065 3071
46. M.F.G. Verberg, M.J.C. Eijkemans, and N.S. Macklon The clinical significance of the retrieval of a low number of oocytes following mild stimulation for IVF: a meta-analysis Hum. Reprod. Update 15 2009 5 12
47. T.E.M. Verhagen, D.J. Hendriks, and L.F.J.M.M. Bancsi The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis Hum. Reprod. Update 14 2008 95 100
48. P.Y.K. Yong, S. Brett, and D.T. Baird A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment Fertil. Steril. 79 2003 308 315